TC Biopharm (NASDAQ:TCBP) Trading Up 14.8% – Should You Buy?

TC Biopharm (Holdings) Plc (NASDAQ:TCBP)’s share price traded up 14.8% on Friday . The stock traded as high as $7.75 and last traded at $7.59. 370,231 shares traded hands during mid-day trading, an increase of 45% from the average session volume of 255,900 shares. The stock had previously closed at $6.61.

TC Biopharm Stock Performance

The company has a current ratio of 0.88, a quick ratio of 0.88 and a debt-to-equity ratio of 1.31. The company has a 50 day simple moving average of $5.51 and a 200-day simple moving average of $9.58.

About TC Biopharm

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.